NDAORALTABLET
Approved
Apr 2011
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
1
Data completeness
5/8 — Partial
DUEXIS (famotidine; ibuprofen) by Amgen is histamine-2 (h2) receptors. First approved in 2011.
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DUEXIS is a fixed-dose combination oral tablet containing famotidine (an H2-receptor antagonist) and ibuprofen (an NSAID) approved by the FDA in April 2011. Famotidine works by inhibiting gastric acid secretion through H2-receptor antagonism, reducing both acid concentration and volume while proportionally decreasing pepsin secretion. The combination is designed to provide gastroprotection while delivering anti-inflammatory and analgesic benefits from ibuprofen. This product addresses the need for concurrent acid suppression in patients requiring chronic NSAID therapy.
$0.0BPart D
2mo to LOEMechanism of Action
histamine-2 (H2) receptors. The primary clinically important pharmacologic activity of famotidine is inhibition of gastric secretion. Both the acid concentration and volume of gastric secretion are suppressed by famotidine, while changes in pepsin secretion are proportional to volume output.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis
Started Apr 2012
12 enrolled
Juvenile Idiopathic Arthritis
Why This Matters for Your Career
Worked on DUEXIS at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.